Table 1 Characteristics of genetically modified mouse models that were more commonly used in the study of anti-Aβ immunotherapies
Mouse line | Age of parenchymal Aβ deposition | Amount of CAA | Age of CAA Deposition | Crosses with other lines described in this review | Commercial availability |
|---|---|---|---|---|---|
PDAPP | 6–9 months [8] | Moderate [9] | Extensive CAA at 22 months [9] | GFP-fluorescent microglia (expressed on Cx3Cr1 promoter) [31] | |
5XFAD B6SJL 5XFAD C57BL/6J | 1.5 months [11] 4 months [12] | Very Low [13] Low [12] | Some CAA in E4FAD [15] at 8–10 months [12] | GFP-microglia, APOE2/3/4 [15] APOE4 [12] | Jackson Laboratory Stock #034840 Jackson Laboratory Stock #034848 |
Tg2576 | 11–13 months [17] | High [18] | By 19 months most pial arteries are affected [18] | None discussed here | Taconic Biosciences Stock #1349 |
3xTg | 6 months [13] | Low [21] | ~ 12 months [21] | None discussed here | Jackson Laboratory Stock #034830 |
APP/PS1 | 3–4 months [23] | Not prominent [24] | Not prominent [24] | None discussed here | Jackson Laboratory Stock #034832 |
APP23 | 6 months [25] | Moderate/high with aging [27] | ~ 19 months [27] | None discussed here | Jackson Laboratory Stock #030504 |
hAPP | 7 months [30] | None reported [30] | None discussed here | Jackson Laboratory Stock #034836 |